HCA's Q3 beat follows a quarter where cash flow fell as profit rose

HCA Healthcare’s inbox of headlines filled up fast this morning. A report describes the hospital operator beating on revenue in third-quarter 2026 results released today, and shares reacted; a wire-service recap repeats the headline numbers, and the company’s own release is being picked apart across the newswires. A separate piece asks what is drawing fresh attention to the stock. None of it directly, and a fifth story, unrelated to HCA itself, covers Surgery Partners’ agreement to be acquired, adding to the day’s attention on hospital operators generally. None of the coverage answers the question a filings-based read would ask first: is HCA turning its reported profit growth into cash, or is the gap between the two getting wider?

HCA’s Q3 numbers aren’t in the filing data yet

The structured SEC data behind this analysis ends at the second quarter of 2026, the period covered by HCA’s 10-Q filed on 28 July. That is the latest full set of figures available for a trailing-twelve-month read. The third-quarter results now circulating were only released this morning; the SEC’s XBRL data for that quarter has not yet been filed and processed, so none of the specific revenue, margin or income figures in those reports can be checked here. What can be checked is the trend those new figures are arriving on top of.

Through the second quarter, profit was rising while cash fell

Over the twelve months to 30 June 2026, HCA’s net income rose 14.6% year on year. Operating cash flow fell 6.8% over the same period, and free cash flow fell 17.8%.

Capex kept rising as the margin narrowed

Capital expenditure rose 10.4% year on year on a trailing basis, even as operating cash flow fell. The combination pushed HCA’s free cash flow margin down 2.3 percentage points year on year. The margin stood at 7.7% of revenue for the trailing twelve months. A hospital operator spending more on facilities and equipment while cash generation slows is not unusual during an expansion phase, but it is the kind of detail a single quarter’s revenue beat does not resolve on its own.

The share count fell 9% as repurchases ran at $8.7bn

Diluted shares outstanding fell 9.0% year on year through the second quarter. Over the same trailing period, HCA’s cash flow statement recorded $8.7bn spent on share repurchases. The filings show both figures; they do not establish that the repurchases caused the share count to fall, only that the two occurred together.

Why cash conversion, not revenue, will decide HCA’s value

HCA’s model value, built from a two-stage discounted cash flow of normalised free cash flow, is sensitive to both margin and growth, but not equally. If the past year’s fall in free cash flow margin persisted, the model value would fall 25.0%. That compares with a 35.4% fall in model value under a lower-growth scenario, and a 46.2% rise under a higher-growth scenario. A 1 percentage point higher discount rate would lower model value by 21.2%. The model’s base case assumes stage-one growth of 7.3%, matching HCA’s trailing revenue growth rate. These are model values under stated assumptions, not a comparison with the share price.

A faster revenue trend could still turn the cash figures around

The strongest case against reading too much into the second-quarter divergence is that revenue growth itself has been accelerating: trailing revenue growth was 7.3% through the second quarter of 2026, up 0.6 percentage points from the prior quarter’s trailing rate. If the newer quarter’s reported beat reflects a genuine pickup in volumes or pricing, rather than one-off items, the free cash flow trend could narrow again once that growth works through the cash flow statement. The filings available here cannot confirm or rule that out. The next 10-Q, covering the third quarter, will be the first chance to test it against actual cash figures rather than headline revenue.